tbuckley/cabot-search huggingface dataset:
Abstracts: Heavy Metals in the Environment IV
Authors: B Shafroth, W Doyle, J Jacobs, Pixea Willis, R Walter, J Stanford
Journal: Environmental Health Perspectives (1976)

During the past two years we have proceeded to develop a proton-induced x-ray emission analysis (PIXEA) system for quantitative analyses of biological and environmental samples.The method employs a 3-MeV proton beam to excite characteristic x-ray emission from the irradiated sample.Typical sensitivi- ties for the PIXEA system are 1-100 ppm (dry weight) for most elements in the region between Cl (Z=17) and Pb (Z=82).
CONTEMPO '89
Authors: Carin M. Olson
Journal: JAMA (1989)

This is the tenth in a nearly annual series of<i>JAMA</i>CONTEMPO issues. Over the years, their purpose has remained unchanged: to keep physicians informed of recent developments in various areas of medicine, through brief descriptions by specialists in each field. The inaugural issue in February 1978 contained 18 articles written principally by members of<i>JAMA</i>'s Editorial Board. Subsequent editions reached beyond the Board for expertise, to cover a broader range of topics. The number of articles has gradually increased; this year's CONTEMPO encompasses 41 subjects. This expansion is limited by page allocations, so not all areas of medicine can be addressed every year. In early CONTEMPO issues, the Medical News &amp; Perspectives section featured personal profiles. The 1984 CONTEMPO was the first to carry that section greatly enlarged. This page increase permits coverage of such a broad topic as this year's highlight, military medicine. The editor of the
Studying human airway pharmacology in microsections: application of videomicrometry
Authors: D.T. Schmidt, G. Dent, E. Rühlmann, N.M. Muñoz, A.R. Leff, K.F. Rabe
Journal: European Respiratory Journal (1999)

Differences in the inflammatory response and prognosis of cryptogenic fibrosing alveolitis (CFA) and that associated with systemic sclerosis (FASSc) are beginning to emerge. It is hypothesized that these differences may be reflected in a distinct pattern of T-helper (Th)-1 and Th-2-type cytokines. Open lung biopsies were obtained from clinically well-documented cases of CFA and FASSc and, as a control, compared with grossly and histologically normal parenchyma obtained from smokers whose lungs were resected for cancer (n=5 in each group). In situ hybridization (ISH) was applied to the samples using anti-sense and sense 35S-labelled riboprobes to detect messenger ribonucleic acid (mRNA) for interleukins (IL)-2, IL-4, IL-5 and interferon (IFN)-gamma. Between 52-91% of cells expressing the cytokines studied were present in the alveolar interstitium rather than in lumenal cells or the alveolar epithelial lining. The highest values for all four cytokines were present in the patients with FASSc, i.e., 22-39 ISH positive cells x mm(-2) alveolar tissue compared with 1-19 cells x mm(-2) and 4-5 cell x mm(-2) in CFA and control subjects, respectively. Whereas the proportions of the four cytokines in FASSc were similar to the control subjects, IL-4 and IL-5 predominated significantly in CFA (p&lt;0.001). For example, the ratio of IL-5 to IFN-gamma was 22:1 in CFA, significantly higher than in the cases with FASSc (2:1) or the control subjects (4:1) (p&lt;0.05). In conclusion, cryptogenic fibrosing alveolitis is an inflammatory condition which is characterized, like asthma, by a predominance of gene expression for T-helper-2-type regulatory cytokines, whereas cryptogenic fibrosing alveolitis associated with systemic sclerosis appears to have a distinct mixed T-helper-1/T-helper-2 functional phenotype and a greater number of cells expressing each of these pro-inflammatory cytokines.
State Medical Associations and Examinations and Licensure
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viral Hepatitis
Authors: Robert W. McCollum
Journal: JAMA (1969)

<h3>Viral hepatitis</h3> Viral hepatitis continues to present a vast array of important, intriguing, and perplexing questions. This situation is not likely to change drastically until specific virologic and serologic methods of study are readily available. Knowledge of the etiologic agents of the two forms, infectious (IH) and serum (SH) hepatitis, has been derived largely from controlled human transmission studies which, in turn, have provided for the systematic observation of epidemiologic and clinical features as well as the collection and preservation of serial serum specimens to serve as invaluable reference materials in the future. The clinical similarity of IH and SH offers a major problem in accurate differential diagnosis. The etiologic agents may be closely related but they are antigenically distinct. They may also differ significantly in their immunogenicity. There is ample evidence, both direct and indirect, in support of a specific immune response following IH infection, eg, direct homologous rechallenge in
AMERICAN ASSOCIATION OF OBSTETRICIANS AND GYNECOLOGISTS
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply:
Authors: Xiuchan Guo, Randy Johnson, Stephen J. O'Brien
Journal: Hepatology (2011)

We do appreciate that there are legitimate differences of opinion with respect to correction for multiple tests as the letter by Dr. Liu aptly illustrates. Our study1 was designed to replicate a previously published previous genome-wide association study.2 One opinion is, in this case, that a correction for multiple comparisons is unnecessary. In our study, however, we still address it. We state that a Bonferroni test may be too conservative given the nonindependence of adjacent single-nucleotide polymorphisms (SNPs) strongly associated by linkage disequilibrium3 (see Guo et al.1 for our detailed discussion of linkage disequilibrium statistics on genome-wide association studies). Nonetheless, even if we concede to the more stringent statistical correction offered by Dr. Liu in his comment (0.05/8 = 0.00625 for table 2 and 0.05/12 = 0.00417 for table 3), nearly all the associations for SNP alleles (table 2) or genotypes (table 3) still achieve statistical significance after correction. Only rs3135021 fails significance. We feel that our data are robust and statistically strong in support of the associations of the SNP alleles, genotypes, and haplotypes illustrated in table 2 to table 4 and figure 1. The statistical power of our study for the additive model is 89%-100%, based on case number, control number, disease prevalence (0.08), significance level (0.05), disease allele frequency (0.334–0.797), and genotype relative risk (1.5). Also, the data reported in table 2 were actually from Armitage's trend test (computed with SAS Genetics software), which is most useful when there is an additive allele effect on the disease susceptibility. As for the direction (i.e., the polarity of odds ratios [ORs]), this format is also a matter of taste. We chose to base our tables on the risk allele (protective allele as a reference) with OR < 1.0, which we state. For example, for rs2395309, the OR should be 1/0.71 = 1.41, and 95% confidence interval should be 1.16–1.69 (formula is 1/0.86 = 1.16, 1/0.59 = 1.69) for risk allele G. We realize that use of the term "risk allele" might be confusing, because some alleles protect whereas others are susceptible, as indicated by the OR. For this confusion, we stand corrected. We apologize for the confusion, but when one examines the OR, it seemed clearly stated to us. For table 3, we list the reference group (OR = 1.0), and the most common genotype was used as a reference for each SNP. Xiuchan Guo M.D.*, Randy Johnson Ph.D. , Stephen J. O'Brien Ph.D. , * HIV Incidence and Case Surveillance Branch National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD.
Identified
Authors: Helena Jenkinson
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Poster Presentations
Authors: Allan Anderson, Med City, Dallas Hosp, Aaron Dallas, Henry Kugelmass, M Ford, Phillip Brown, Lynn Tarkington, Hca Ccmn, April Simon, Edmund Becker, Steven Culler, Marc Katz, Lee Arcement, Med Cntr, L Metairie, Ron Horswell, Kathy Hebert, Joan Breen, Donna Snyder, Kerry Querry, Aaron Kugelmass, Henry Ford Hosp, David Cohen, Sophia Meis, Richard Snow, Michelle Lalonde, Lisa Hindman, Kathy Spencer, Teresa Glaser, ; Mcconnell, Deborah Ehrenthal, Edward Ewen, Lisa Maxwell, ; Christiana
Journal: Circulation (2006)

Objective: Stroke is the third leading cause of death and the leading cause of serious, long-term disability in the United States.Each year, over 700,000 people suffer a new or recurrent stroke.The objective of this investigation is to examine the impact of gender on stroke outcomes.Methods: Using the HCA Casemix database, an administrative database of all admissions to any HCA hospital, all 56,417 consecutive admissions with an embolic, thrombotic, or ischemic stroke from 1-1-03 thru 12-31-04 were analyzed.Patient comorbidities, procedures, and complications were identified using ICD9 codes.Univariate and multivariate regression analyses controlling for patient characteristics and comorbid conditions were used to analyze in-hospital mortality, pneumonia, mechanical ventilation, and discharge home.Findings: The 166 study hospitals averaged 340 stroke patients.Women represented 56% of the patients.Women were significantly older regardless of the type of stroke (73 yrs.Versus 67 yrs, pϽ0.001).Ischemic stroke was the largest group representing 82.5% of all strokes, followed by embolic (12.2%) and thrombotic (5.3%).There were no significant differences in the percentage of women or men in any of the three stroke groups.There were also no significant differences in the long-term use of anticoagulants, aspirin, or antiplatelet therapy based on gender.The use of thrombolytic therapy was low overall, with women receiving it less often than men (1.28% vs. 1.70%, pϽ0.001).Adjusted outcomes (odds ratios) by gender are reported below.Conclusion: Men, despite their younger age, are more likely to die (OR 1.08, pϭ0.044) or develop pneumonia (OR 1.90, pϽ0.001).However, men, if they survive, are significantly more likely to be discharged home than women (OR1.15,pϽ0.001).Given the dire consequences of stroke, further research is needed to improve the outcomes of both men and women.
Dietary oat fiber sources and blood lipids
Authors: G. M. Koval
Journal: JAMA (1992)

To the Editor.—Cooper et al<sup>1</sup>have recently reviewed the variations and practical utility of blood lipid measurements and have suggested that oat bran has only a modest cholesterol-lowering effect, and that dietary fiber grain supplements reduce cholesterol levels mainly because they replace dietary saturated fats. They base their conclusions primarily on a publication by Swain et al<sup>2</sup>; however, additional studies have since examined the relationships between dietary fiber, diet, and blood lipids, and have concluded that the cholesterol-lowering effects of fiber are not strictly a function of dietary substitution.<sup>3-5</sup> Anderson et al<sup>3</sup>studied 20 hypercholesterolemic men in the metabolic ward who were randomly allocated to either oat bran or wheat bran for 21 days after a 7-day control-diet period. Control and treatment diets were designed to be identical in energy content and nutrients, and differed only in the amount of soluble fiber. Oat bran significantly decreased
The 1938 Year Book of Neurology, Psychiatry and Endocrinology. Edited by<i>Hans H. Reese, M. D.</i>(Neurology),<i>Harry A. Paskind, M. D., Ph. D.</i>(Psychiatry),<i>Elmer L. Sevringhaus, M. D.</i>(Endocrinology). (Chicago: The Year Book Publishers. 1939.)
Authors: C. B. F.
Journal: American Journal of Psychiatry (1939)
Healthcare Architecture
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
221 20-YEAR PROTOCOL LIVER BIOPSIES: INVASIVE BUT USEFUL FOR THE MANAGEMENT OF LIVER RECIPIENTS
Authors: M. Sebagh, D. Samuel, T.M. Antonini, A. Coilly, D. Degli Esposti, B. Roche, V. Karam, A. Dos Santos, J.-C. Duclos-Vallee, A.-M. Roque-Afonso, E. Ballot, C. Guettier, F. Blandin, F. Saliba, D. Azoulay
Journal: Journal of Hepatology (2012)
The blood-brain barrier in primary CNS lymphomas: Ultrastructural evidence of endothelial cell death
Authors: Peter P. Molnár, Brian P. O'Neill, Bernd W. Scheithauer, Dennis R. Groothuis
Journal: Neuro-Oncology (1999)

The vasculature of 24 primary CNS B-cell lymphomas that were not related to acquired immunode ciency syndrome was systematically studied by electron microscopy.Seven low-grade astrocytic tumors were included for comparison.Classical electron microscopy features of apoptosis were found in lymphoma cells of 21 of 22 subjects.Capillaries of gliomas and lymphomas showed changes reported previously: variability of endothelial cell (EC)-thickness and number, basal lamina thickness and duplication, and fenestrations.Primary CNS B-cell lymphoma ECs showed two distinctive populations of electron-dense and electron-lucent cells.The electron-dense ECs occurred in 38% of all capillaries, with changes consisting of chromatin condensation in bizarre and contracted nuclei, cytoplasmic shrinkage with markedly increased electron density, and dilatation of the endoplas-mic reticulum.We interpreted these changes as indicative of apoptosis.Cell death eventually resulted in complete disintegration of the endothelium with frank discontinuities of the EC component of the blood-tumor barrier in capillaries and postcapillary venules.Another population of ECs had increased cell volume, conspicuous cytoplasmic electron lucency, dispersed organelles, scattered vesicles, and apical stress bers.We interpreted these changes as indicative of cellular regeneration.Individual apoptotic ECs often lay next to normal or regenerating ECs.Neither type of EC change was observed in gliomas, which also lacked perivascular neoplastic lymphocytic cuf ng.We believe that these populations of ECs, which have not been described in other disorders affecting the bloodbrain barrier, may be induced by cytokines released from necrotic and/or apoptotic tumor lymphocytes and may explain the unusual imaging characteristics of primary CNS B-cell lymphomas treated with corticosteroids.
Intercurrent complications in chronic alcoholic men admitted to the intensive care unit following trauma
Authors: C. D. Spies, B. Neuner, T. Neumann, S. Blum, C. M�ller, H. Rommelspacher, A. Rieger, C. Sanft, M. Specht, L. Hannemann, H. W. Striebel, W. Schaffartzik
Journal: Intensive Care Medicine (1996)
Reversible insufficiency in chronic renal disease
Authors: G. L. Ackerman
Journal: JAMA (1966)

When renal function is decreased to approximately 30% of normal, further decreases, even though minor, produce major changes in the blood urea nitrogen level. In the presence of chronic renal disease such a change may precipitate uremia in a previously compensated patient. An important feature of the management of patients with chronic renal failure is the recognition and correction of conditions that lead to further deterioration of already compromised renal function. Sodium depletion and hypovolemia, urinary tract obstruction, systemic or renal infection, and major surgery of trauma are common causes of reversible uremia in patients with chronic renal failure. Discovery and treatment of these complications may relieve symptoms and prolong life in patients whose outlook is otherwise hopeless.
LOCAL ANESTHESIA IN OPERATIONS FOR MASTOIDITIS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AIDS-associated virus yields data to intensifying scientific study
Authors: C. Marwick
Journal: JAMA (1985)

The number of cases of acquired immunodeficiency syndrome (AIDS) continues to rise. By early fall, more than 14,400 cases had been reported to the Centers for Disease Control in Atlanta. The agency predicts that—by midsummer 1986— there will be an additional 12,000 cases. James W. Curran, MD, chief of the center's AIDS branch, and his associates estimate that as many as a million Americans are now infected with human T-cell lymphotropic virus type III (HTLV-III), the virus generally held to be the primary cause of AIDS (<i>Science</i>1985;229:1352-1357). In many reports, the AIDS virus is also called the lymphadenopathyassociated virus (LAV), the name proposed by the French group headed by Luc Montagnier, MD, who originally isolated this virus. For his part, Robert C. Gallo, MD, chief of the Laboratory of Tumor Cell Biology at the National Cancer Institute (National Institutes of Health, Bethesda, Md) and the American discoverer of the
PORTRAIT OF A PATHOLOGIST
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal